Drug intelligence / Profile preview

Karika

Development stage: Phase 3
Modality: Small Molecules
Administration: Oral

Overview

Karika is an herbal formulation syrup composed of Carica papaya leaf extract and Tinospora cordifolia. It is currently being evaluated in clinical studies for its effect on thrombocyte count, particularly in patients experiencing low platelet counts associated with conditions such as dengue, malaria, typhoid, chikungunya, and other viral infections. The formulation is also noted for its potential anti-inflammatory and antipyretic activities.

Brand names: Karika Syrup
Other names: Carica papaya + Tinospora cordifolia syrup

Targets

CYP3A4 (Cytochrome P450 3A4)CYP2C8 (Cytochrome P450 2C8)CYP1A2 (Cytochrome P450 1A2)

Beyond the preview

Go deeper on Karika.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Karika.

Explore the full profile